Tumour necrosis factor inhibitor-associated sinusitis

Rhinology

Volumn 52, Issue 3, 2014, Pages 246-251

  Yoshihara, Shintaro ^a   Kondo, Kenji ^a   Kanaya, Kaori ^a   Suzukawa, Keigo ^a   Baba, Shintaro ^a   Toma Hirano, Makiko ^a   Kikuta, Shu ^a   Iwasaki, Yukiko ^a   Fujio, Keishi ^a   Yamasoba, Tatsuya ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

etanercept; infiximab; sinusitis; TNF inhibitor

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; DISEASE PREDISPOSITION; DRUG ANTAGONISM; FEMALE; HUMAN; IMMUNOLOGY; MAXILLA SINUSITIS; MIDDLE AGED; RADIOGRAPHY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAXILLARY SINUSITIS; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908067518     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: 10.4193/Rhino13.074     Document Type: Article

References (24)

1. Saag KG, Teng GG, Patkar N, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumat-ic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-784.
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64: 625-639.
3. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006; 36: 159-167.
4. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155.
5. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma forma-tion in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lympho-toxin. J Immunol 1999; 162: 3504-3511.
6. Kaene J, Gershon S, Wise R P, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
7. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-1133.
8. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-2339.
9. FDA Arthritis Advisory Committee [Web site]. US Food and Drug Administration Update on the TNF-a blocking agents. March 4, 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF.Briefing.htm. Accessed Nov 27, 2012.
10. Michaud K, Wolfe F. The association of rheu-matoid arthritis and its treatment with sinus disease. J Rheumatol 2006; 33: 2412-2415.
11. Haroon M, Bond U, Phelan M. Sinusitis: a possible link with adalimumab. Clin Rheumatol 2008; 27: 1189-1190.
12. Fokkens WJ, Lund VJ, Mullol J et al. EPOS 2012: European position paper on rhinosi-nusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50: 1-12.
13. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
14. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008; 47: 339-344.
15. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope 2003; 113: 1199-1205.
16. Kim DH, Jeon EJ, Park SN, Park KH, Park YS, Yeo SW. Effects of a tumor necrosis factor-α antagonist on experimentally induced rhi-nosinusitis. J Biomed Biotechnol 2011; 2011: 360457.
17. Yung MW, Gould J, Upton GJ. Nasal poly-posis in children with cystic fibrosis: a long term follow-up study. Ann Otol Laryngol 2002; 111: 1081-1086.
18. Gentile VG, Isaacson G. Patterns of sinusitis in cystic fibrosis. Laryngoscope 1996; 106: 1005-1009.
19. Decker CF. Sinusitis in the immunocom-promised host. Curr Infect Dis Rep 1999; 1: 27-32.
20. Ortiz E, Ng RT, Alliegro FC, Teixeira C, Muranaka EB, Sakano E. Microbiology of rhinosinusitis in immunosupressed patients from the University Hospital. Braz J Otorhinolaryngol 2011; 77: 522-525.
21. Ishitoya J, Sakuma Y, Tsukuda M. Eosinophilic chronic rhinosinusitis in Japan. Allergol Int 2010; 59: 239-245.
22. Suzaki H, Kudoh S, Sugiyama Y, Maeda H, Nomura Y. Sinobronchial syndrome in Japanese people. Am J Rhinol 1990; 4: 133-139.
23. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007; 45: 259-267.
24. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007; 45: 259-267.